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Abstract
Background: Transplantation of endothelial progenitor cells (EPCs)/endothelial cells (ECs) has been used for the
treatment of ischemic diseases and hemophilia A, due to their great capacity for producing factor VIII and for
repairing vascular damage. We established an effective approach to stimulate the expansion and differentiation
of EPCs for potential therapeutic applications.
Methods: CD34+ cells isolated from human cord blood were cultured in a two-step system for 21 days. The
generated adherent cells were characterized via flow cytometry and immunofluorescent staining. Moreover,
single-cell clonogenic and tube-forming assays were carried out to evaluate their potential to proliferate and form
vessel networks. Furthermore, these cells were transplanted into a mouse model of hepatic sinusoidal endothelium
injury by hepatic portal vein injection to investigate their in-vivo behavior.
Results: The two-step culture protocol promoted the expansion and differentiation of human cord blood CD34+
cells efficiently, resulting in a large number of adherent cells within 3 weeks. The generated adherent cells were
identified as EPCs/ECs based on the expression of CD31, CD144, vWF, and FVIII, and cell numbers showed a
1400-fold increase compared with the initial number. Moreover, these EPCs/ECs were capable of proliferating and
establishing colonies as individual cells, and forming tube-like structures. More significantly, tissue examination of
mice after transplantation revealed that the injected EPCs/ECs migrated and integrated into the liver, reconstituting
the sinusoidal endothelial compartment.
Conclusions: We developed an approach for the generation of cord blood-derived EPCs/ECs on a large scale,
characterized them phenotypically, and demonstrated their in-vivo functional capacity. Our approach provides an
excellent source of healthy EPCs/ECs for use in cell therapy in a clinical setting.
Keywords: Endothelial progenitor cells, Human cord blood CD34+ cells, Expansion and differentiation, Hepatic
sinusoidal endothelium injury, NOD/SCID mice
Background
Endothelial differentiation was traditionally believed to
occur exclusively during embryonic development after the
differentiation of mesodermal cells to angioblasts [1]. In
1997, Asahara et al. [2] first proposed that CD34+ mono-
nuclear blood cells isolated from human peripheral blood
can differentiate ex vivo into an endothelial phenotype
and participate in angiogenesis. This finding represented a
milestone in the discovery and definition of endothelial
progenitor cells (EPCs). Thereafter, many pioneering
studies were conducted to reveal the role of EPCs in the
physiological functions of wound healing and the patho-
genesis of ischemic diseases [3–6]. Recently, the thera-
peutic applications of EPCs in treating hemophilia A
(FVIII-deficient disease) were reported, because EPCs can
differentiate into mature endothelial cells (ECs) to pro-
duce FVIII [7–12]. These cells can thus be regarded as an
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important source of FVIII, and can be used as a novel cell
therapy for neovascularization.
EPCs are thought to be derived from bone marrow,
and can be isolated from adult peripheral or umbilical
cord blood [13–15]. However, EPCs represent a very
small proportion of the cells in the circulation, ranging
from 0.002 to 0.01% in peripheral blood and from 0.2 to
1% in umbilical cord blood. Although they can expand
exponentially, migrate efficiently to sites of neovasculari-
zation, and differentiate into ECs in ex-vivo studies [16,
17], the number of cells is limited in the systemic infu-
sion of allogenic EPCs in patients. Difficulties in obtain-
ing adequate numbers of cells for transplantation
currently restrict their use in clinical treatments [18].
EPCs from circulating mononuclear cells (MNCs) have
been defined as early EPCs and late EPCs. Early EPCs share
a number of cell-surface markers with hematopoietic stem
cells (HSCs) such as CD34, CD133, and Tie-1/2 [19, 20],
and secrete many stem cell growth factors such as granulo-
cyte colony stimulating factor (G-CSF), stem cell factor
(SCF), and interleukin (IL)-6/11 [21, 22]. A recent publica-
tion reported that cytokines such as SCF, FMS-like tyrosine
kinase 3 ligand (Flt-3 L), and IL-3 could be applied for
successful nonadhesive expansion of early EPCs for effect-
ive treatment of ischemia [23].
In the current study, an innovative and efficient culture
system for the expansion and differentiation of cord blood
CD34+ cells to generate EPCs was explored successfully. A
new two-step system for EPC culture was developed, in
which stem cell cytokines SCF, Flt-3 L, IL-3, thrombopoie-
tin (TPO), and granulocyte-macrophage colony-stimulating
factor (GM-CSF) combined with endothelial growth factors
including vascular endothelial growth factor (VEGF),
insulin-like growth factor (IGF), epidermal growth factor
(EGF), fibroblast growth factor (FGF), and fibronectin (FN)
were applied to the cord blood CD34+ cells. The generated
EPCs/ECs were characterized by a specific endothelial
phenotype and transplanted into nonobese diabetic/severe
combined immunodeficient (NOD/SCID) mice to recon-
struct the injured hepatic sinusoidal endothelium, which
expressed factor VIII and other endothelial functional
factors. Our study will lead to the establishment of a new
expansion system for EPCs, and an improvement in the
potential use of EPCs/ECs to treat ischemic diseases and
hemophilia A in a clinical setting.
Methods
Ethics statement
All of the human cells or tissues used in this study were ob-
tained from healthy newborn donors in Suzhou Municipal
Hospital (Suzhou, China) after mothers’ written informed
consent. The study was approved by the Hospital’s Ethics
Committee and Research Ethics Advisory Committee
(Permit Number 2014SZSLK073).
All research involving animals was conducted according
to relevant national and international guidelines. NOD/
SCID mice (18–22 g, male, 6–8 weeks old) were obtained
from SLAC Laboratory Animal Co. (Shanghai, China),
and experiments were performed in accordance with the
Guidelines and Policies for Animal Surgery provided by
the SPF Animal Lab (Animal Experimental Center of
Soochow University, Suzhou, China). All surgeries were
performed under anesthesia, and efforts were made to
minimize the suffering of the animals. All experiments
carried out on mice were approved by the Institutional
Animal Use and Care Committee of Soochow University
(IACUC Permit Number SYXK (Su) 2014-0078).
Isolation of CD34+ cells from cord blood
Human umbilical cord blood samples (70–100 ml each; n
= 10) were collected in sterile blood packs containing
citrate–dextrose solution as the anticoagulant. After a
Ficoll Hypaque (density 1077 g/cm3; GE Healthcare,
Norway) density gradient centrifugation, the MNCs were
isolated, washed twice, and suspended in sterile PBS with
0.5% BSA and 2 mM EDTA. CD34+ cells were separated
from MNCs by a magnetic bead separation method
(Miltenyi Biotec, Germany). In brief, the total MNCs were
labeled with mouse anti human CD34 mAb coupled with
microbeads (MACS). The bead-positive cells (MNC-CD34
+) were enriched on positive-selection columns set in a
magnetic field. Flow-cytometric analyses of purified cells
using a PE-conjugated mouse anti human CD34 mAb (BD
Biosciences, USA) showed that 94.1 ± 5.3% of the selected
cells were positive for CD34.
Cell culture of EPCs
The culture system to expand and differentiate EPCs
was divided into two steps:
(1)Step I (days 0–6) involved the proliferation of
MNC-CD34+ cells. In this step, 2 × 105 cells/ml were
seeded into the 24-well plates in Iscove’s modified
Dulbecco’s medium (IMDM) and subcultured
immediately when the cell density reached over
1 × 106/ml. Cytokines SCF (200 ng/ml), Flt-3 L
(200 ng/ml), TPO (20 ng/ml), IL-3 (10 ng/ml),
GM-CSF (12.5 ng/ml), and VEGF (50 ng/ml)
were added to the IMDM medium to promote
proliferation of the suspended CD34+ cells.
The markers CD34, CD133, and VEGFR-2
(BD Biosciences, USA) were tested by flow
cytometry for the identification and quantification
of the CD34+ cells and EPCs.
(2)Step II (days 7–21) involved the expansion and
differentiation of EPCs from proliferated CD34+
cells. EBM-2 basal medium (LONZA, Switzerland)
supplemented with VEGF (25 ng/ml; PeproTech,
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USA), IGF (20 ng/ml; PeproTech), EGF (10 ng/
ml; PeproTech), b-FGF (10 ng/ml; PeproTech),
FN (5 μg/ml; Sigma-Aldrich, USA), ascorbic acid
(2 μg/ml; Sigma-Aldrich), heparin (100 U/ml;
Sigma-Aldrich), hydrocortisone (100 ng/ml;
Sigma-Aldrich), L-glutamine (4 mM; Life
Technologies, USA), and 20% FBS (Life
Technologies) was used to culture the EPCs.
Cells were seeded at 1 × 106 cells per well into
the 24-well plates, which were precoated with FN
(2.5 μg/cm2) at 37 °C for 2 h. The supernatant
medium and nonadherent cells were removed on
day 9, and the adherent cells were continued to
be cultured in the same manner to day 21. The
morphological changes were monitored using an
Olympus IX51 inverted microscope (Olympus
Corporation, Japan).
Flow cytometry
Adherent cells were first detached using trypsin and col-
lected together with suspended cells in PBS. The cells were
then incubated with antibodies or the IgG isotype control
for 30 min at room temperature. The antibodies used were
PE-conjugated mouse anti-human CD34 mAb, APC-
conjugated mouse anti-human CD133 mAb, PE-conjugated
mouse anti-human VEGFR-2, APC-conjugated mouse anti-
human CD31 mAb, FITC-conjugated mouse anti-human
CD144 mAb, PE-conjugated mouse anti-human CD45
mAb, and PE-conjugated mouse anti-human CD14 mAb
(BD Biosciences). Data were collected on a FACSVerse flow
cytometer (BD Biosciences) and analyzed with FlowJo.
Vascular tube formation assay
Prechilled 96-well plates were coated with 50 μl Matrigel
basement membrane matrix (BD Biosciences) per well and
incubated for 1 h at 37 °C. EPCs were seeded on top of the
gelled Matrigel at 2.5 × 104 cells in 100 μl step II medium.
After incubating for 10 h, endothelial network formation
was examined and representative fields were photographed
under a microscope (Olympus Corporation).
Immunostaining
Cells were fixed with 4% paraformaldehyde for 15 min at
room temperature. Primary antibodies used were rabbit
anti-human CD31 (1:500; Abcam, UK), mouse anti-
human vWF (1:250; Cell Signaling Technology, USA),
and mouse anti-human FVIII (1:500; Abcam). Cells then
were incubated with fluorescent-labeled secondary anti-
bodies including Cy3-labeled donkey anti-rabbit IgG
(1:1000; Jackson ImmunoResearch, USA) and FITC-
labeled donkey anti-mouse IgG (1:1000; Jackson Immu-
noResearch). Nuclei were counterstained with 1 mg/ml
4,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) for
10 min. The stained cells were imaged using a confocal
microscope (FV1000; Olympus Corporation), and then
the fluorescence intensities were measured in the result-
ing images using ImageJ software/Olympus.
Western blot
Cells were washed with cold PBS and then lysed with
protein extraction reagent. The lysates were centrifuged
at 12,000 rpm at 4 °C for 15 min to remove cell debris
and the supernatants were transferred to fresh tubes.
Protein was separated using 10% SDS-PAGE gels and
transferred to a 0.22 μm PVDF membrane at a constant
300 mA for 3 h using a Trans-Blot Electrophoretic
Transfer Cell. After blocking with 5% BSA in TBST
overnight at 4 °C, the membrane was immunoprecipi-
tated with vWF and FVIII primary antibody (rabbit mAb
anti-vWF, 1:1000 and mouse mAb anti-FVIII, 1:500;
Abcam) for 1.5 h at room temperature. Membranes were
then washed and incubated for 1 h at room temperature
with the appropriate horseradish peroxidase-linked sec-
ondary antibody (1:1000; Abcam).
Enzyme-linked immunosorbent assay
Culture supernatants were filtered through a 0.22-μm
filter (Millipore, USA) and subjected to 10-fold concen-
tration. The concentrates of secreted FVIII proteins were
tested by a commercial enzyme-linked immunosorbent
assay (ELISA) kit according to the manufacturer’s proto-
col (Sekisui Diagnostics, USA).
Single-cell clonogenic assay
EPCs were serially diluted and plated onto a 96-well plate.
The wells were examined under an Olympus IX51 inverted
microscope (Olympus Corporation) and only wells contain-
ing a single cell were monitored. After 1 week of culture,
wells were examined for colony growth by visual inspection.
Preparation of GFP lentivirus vector and infection of
EPCs/ECs
The green fluorescent protein (GFP) lentivirus vector
(pSSI13772) was prepared as described previously [12, 24].
Before transplantation, the differentiated/expanded EPCs/
ECs were infected with GFP lentivirus for 2 h supplemented
with polybrene at 8 μg/ml. GFP expression was observed
using a fluorescence microscope (Olympus Corporation).
Over 90% of EPCs/ECs showed green fluorescence 24 h
post infection. Trypsin was used to detach the cells, which
were then centrifuged and suspended in sterile PBS.
Transplantation of EPCs/ECs into NOD/SCID mice
NOD/SCID mice were housed in individual stainless
steel cages in a SPF facility in Soochow University, with
a regulated temperature of 24 ± 2 °C, relative humidity
of 50 ± 10%, and a 12-h light cycle. Forty NOD/SCID
mice were randomly divided into five groups, namely
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control group, blank group, trans-7d group, trans-14d
group, and trans-28d group. Except for the blank group,
acute liver injury was induced in mice by an intraperito-
neal injection of 100 mg/kg monocrotaline (MCT;
Sigma-Aldrich) in saline 24 h prior to the cell trans-
plantation [25]. After anesthesia with FFM mix (2.5 mg/
kg fluanisone, 0.105 mg/kg fentanylcitrate, and 1.25 mg/
kg midozalam HCl in H2O), mice in the blank, trans-7d,
trans-14d, and trans-28d groups were transplanted with
EPCs/ECs (6 × 106 in 100 μl PBS per mouse) via the hep-
atic portal vein using 27-gauge needles (Hamilton,
Switzerland) [12], while the control group mice were
treated with 100 μl PBS. At days 7, 14, and 28 after
transplantation, the mice in the trans-7d, trans-14d, and
trans-28d groups were sacrificed by cervical dislocation,
respectively, and the livers were removed and fixed in
4% formalin for analysis. In control and blank groups,
mice were sacrificed and livers were analyzed 7 days
after transplantation.
Detection of transplanted EPCs/ECs
The hepatic tissues were embedded in Optimum Cutting
Temperature compound (OCT; Sakura, Tokyo, Japan) to
make the cryosections (20 μm; Leica CM1900, Germany).
Twenty-five cryosections were randomly selected from the
liver pieces of each mouse. Immunofluorescent staining
was used to identify EPCs/ECs infected with the GFP lenti-
virus. Cryosections were labeled with rabbit anti-GFP pri-
mary antibody (1:100; Santa Cruz, USA) and Cy3-labeled
donkey anti-rabbit IgG secondary antibody (1:1000; Jackson
ImmunoResearch). Nuclei were counterstained with 1 mg/
ml DAPI (Sigma-Aldrich) for 10 min. These cryosections
were then observed under a fluorescence microscope
(Olympus Corporation). The percentages of GFP staining
cells were quantified using ImageJ software.
Statistical analysis
Except for the in-vivo mouse experiment, which was re-
peated twice, all other experiments were repeated at
least three times. All results are expressed as mean ± SD.
All data were subjected to ANOVA followed by Fisher’s
analysis for comparison between two means.
Results
Proliferation of cord blood CD34+ monocytes in step I of
culture
The number of CD34+ cells has been reported to correl-
ate positively with the endothelial differentiation rate
[23]. In the first step of our culture protocol, a cytokine
combination including SCF, Flt-3 L, TPO, IL-3, GM-CSF,
and VEGF was used to efficiently expand cord blood
CD34+ cells, as well as early EPCs. After 6 days in culture,
the total cell number increased from 1.5 × 105 to 2.68 ×
107 ± 2.90 × 106 cells, showing a ~180-fold proliferation
(Fig. 1a, b). The expression of CD34, CD133, and VEGFR2
markers on days 0 and 6 is shown in Fig. 1e. The initial
percentage of CD34+, CD133+, and VEGFR2+ cells was
94.1 ± 5.3%, 80.3 ± 2.7%, and 0.84 ± 0.16%, respectively.
On day 6, CD34+ cells were maintained at the relatively
high level of 58.6 ± 2.7%, and CD133+ and VEGFR2+ cells
decreased to 27.9 ± 1.8% and 0.14 ± 0.02%, respectively.
Within 6 days, the fold-increase of CD34+ and VEGFR2+
cells was 108 ± 15.6 and 41.9 ± 5.1, respectively (Fig. 1b–
d). Meanwhile, cells exhibited robust suspension growth,
with only a small number of cells showing an adhe-
sive phenotype as early EPCs (Fig. 2a, day 6). These
results indicated that CD34+ cells and early EPCs
both undergo extensive proliferation in step I of the
culture protocol.
Expansion and differentiation of EPCs in step II of culture
Six days after the initial expansion of step I, cells were
transferred to EBM-2 basal medium supplemented with
endothelial growth factors VEGF, IGF, EGF, FGF, and FN.
At various time points, morphological changes in cultured
cells could be observed clearly with a light microscope
(Fig. 2a). Three days later (day 9), the suspended early
EPCs became adherent to the plates, and started to grow
exponentially. From day 15, a typical spindle-like shape
could be observed clearly in the cultured cells. After
21 days following this culture protocol, the differentiated/
expanded EPCs/ECs were collected for analysis. By day
21, the absolute number of VEGFR2+ cells reached 4.72 ×
104 ± 3.74 × 103 cells per well, from 1.4 × 103 cells per well
on day 6, meaning that the EPCs/ECs ultimately under-
went a 1412.03 ± 102.25-fold increase over the initial
numbers of EPCs (Fig. 2b, c). Collectively, these results
demonstrated that this innovative two-step culture system
was effective for the ex-vivo expansion and differentiation
of EPCs/ECs derived from cord blood CD34+ cells.
Characterization of differentiated EPCs/ECs
The cell surface markers during the cell culture process
were monitored by flow cytometry on days 0, 6, 9, 15, and
21. During the differentiation, the expression levels of EC
specific markers CD31 and CD144 were increasing con-
tinuously, with the frequency of CD31+/CD144+ late
EPCs/ECs achieving 99.0 ± 0.8% by day 21 (Fig. 3a, upper
panel). Moreover, the percentage of CD45+ and CD14+
cells was 0.04 ± 0.01% and 0.02 ± 0.01%, respectively, in
week 3, indicating a very small amount of white blood
cells and macrophages in the cell preparations (Fig. 3a,
lower panel). Immunofluorescence analysis of differenti-
ated cells showed that over 90% of the adherent cells
expressed CD31 and vWF by double staining with Cy3
and FITC-conjugated antibodies (Fig. 3b), consistent with
the results obtained by flow cytometric analysis. Moreover,
immunofluorescent staining indicated that over 80% of
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adherent cells were positive for FVIII, indicating the suc-
cessful expression of FVIII in the cell cytoplasm (Fig. 3c).
Meanwhile, the expressions of cytoplasm FVIII and vWF
proteins were confirmed by western blot analyses (Fig. 3d).
In addition, more than 20 ng/ml of FVIII secreted in the
culture media was detected on day 21 to further confirm
the FVIII secreting capacity of induced EPCs/ECs.
In addition, the clonogenic and proliferative potential
of differentiated EPCs was investigated by a single-cell
assay to determine whether a single EPC could prolifer-
ate and form a colony in the absence of other cells. As
shown in Fig. 4a, the single plated EPC showed cell div-
ision from day 3, and formed obvious colonies on day 5.
From day 5 to day 7, the small colonies formed showed
robust proliferation, and the average number of progeny
derived from a single plated cell was more than 350 cells
on day 7. About 20% of the single EPCs gave rise to
large colonies or clusters containing over 500 cells
(Fig. 4b, c). Furthermore, the tube formation assays on
Matrigel showed that cells arranged themselves into ca-
pillaries and formed vascular networks with branching
points (Fig. 4d).
Transplantation of cultured human EPCs/ECs into the
livers of NOD/SCID mice
In order to determine the efficacy of the produced
EPCs/ECs in vivo, an acute hepatic sinusoidal endothe-
lium injury model induced by MCT was established in
NOD/SCID mice. The EPCs/ECs infected with a GFP
lentiviral vector were injected into mice, and at indicated
time points post transplantation the livers were obtained
and analyzed by immunostaining with anti-GFP primary
Fig. 1 Proliferation of CD34+ monocytes and early EPCs derived from human cord blood. The cord blood CD34+ cells were cultured for 6 days in
the modified IMDM medium supplemented with a cytokine cocktail. a Absolute number of total cells and CD34+ cells from day 0 to day 6. b
Fold-increase in proliferation of total cells and CD34+ cells from day 0 to day 6. c, d Absolute number and fold-increase of VEGFR2+ cells from
day 0 to day 6. e Representative flow cytometry profiles of CD34, CD133, and VEGFR2 markers on cells before and after expansion. Data are
mean ± SD; n = 10
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Fig. 2 Expansion and differentiation of EPCs from proliferated CD34+ cells. The ex-vivo expanded human CD34+ cells were cultured with the optimized
medium recipe to induce EC differentiation (scale bar= 50 μm). a Cell morphology imaged with an optical microscope on days 0, 6, 9, 15, and 21. b Absolute
number of VEGFR2+ cells at different time points. c Fold-increase in proliferation of VEGFR2+ cells at different time points. Data are mean ± SD; n= 10
Fig. 3 Phenotypic and functional analysis of differentiated EPCs/ECs. a Representative flow cytometry profiles of CD31, CD144, CD45, and CD14
cell markers on days 0, 6, 9, 15, and 21. b Immunofluorescence analysis of CD31 (red) and vWF (green) double staining on day 21 (scale bar =
20 μm). c Immunofluorescence staining of FVIII in cytoplasm on day 21 (scale bar = 20 μm). d Western blot analysis of cytoplasm FVIII and vWF
proteins on day 21 (Color figure online)
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antibody and Cy3-labeled secondary antibody. The im-
munostaining results revealed that there were almost no
GFP-positive cells in the control and blank groups, but
these GFP-positive cells obviously existed in the hepatic
sections in trans-7d and trans-14d groups (Fig. 5a). The
transplanted cells were observed mostly around the
endothelium of small veins in the hepatic issues on day
7, while they were found scattered in the intercellular
spaces between hepatocytes at the hepatic plates on day
14. Furthermore, quantitative analysis showed that about
1.75 ± 0.34% and 1.13 ± 0.25% of liver cells were ob-
served as GFP-positive staining cells in the livers on days
7 and 14, respectively (Fig. 5b). These results indicated
the cultured EPCs/ECs could migrate into the injured
sites and structurally reconstitute the sinusoidal–endo-
thelial compartment in the liver.
Discussion
EPCs are an attractive resource for enhancing neovascu-
larization in ischemic tissue and producing FVIII in cases
of hemophilia A. However, the low number of cells ob-
tained after purification from peripheral or cord blood is a
common barrier to the clinical use of EPCs. Here, we de-
veloped an innovative two-step system for high-level ex-
vivo expansion and differentiation of human EPCs derived
from cord blood CD34+ cells. Using this protocol, human
EPCs/ECs were efficiently generated from human cord
blood CD34+ cells within 3 weeks, achieving a more than
1400-fold increase in proliferation. Compared with the ap-
proximately 400-fold increase reported in previous studies
[17, 26], our technique showed a remarkable improvement
in the large-scale generation of EPCs/ECs ex vivo. More
than 2 × 108 EPCs/ECs were generated from one cord
blood sample (70–100 ml) within 3 weeks, and afterwards
these EPCs/ECs could also be sustainably cultured ex vivo
for up to 3 months, accompanied by a process of gradual
maturation [27]. This production platform could therefore
provide sufficient functional EPCs/ECs for transplantation
treatments in a clinical setting.
In our study, human umbilical cord blood was use used
to derive CD34+ cells for EPC culture. In contrast to pro-
genitor cells derived from adult bone marrow and adult
peripheral blood, cord blood stem cells possess distinct
proliferation advantages in cell-cycle rate and telomere
length [23]. Moreover, obtaining cord blood is noninvasive
and the cells are genomically stable, in contrast with the
invasive procedure of bone marrow isolation to harvest in-
duced pluripotent cells (iPSCs) [28]. In addition, all of the
cytokines included in the culture system, such as SCF,
TPO, FLT-3, IL-3, GM-CSF, and VEGF, were biological
endogenous factors and are commonly used in clinical
treatments. This treatment would pose no risk of cell
Fig. 4 Clonogenic quantitation of single EPC and vessel-like structures of differentiated ECs. a Cell morphology at different time points by seeding
a single differentiated EPC in an individual well of a 96-well plate. The arrow indicates a single colony on day 0. b, c Percentage and number of
cell progeny at different time points. d Differentiated EPCs/ECs were placed on Matrigel for a 10-h incubation, and representative fields of view
showing endothelial networks were photographed under a microscope (scale bars = 100 μm)
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toxicity or tumor stimulation. The convenience of sample
collection and safety of an ex-vivo culture system could be
easily adapted for large-scale production of EPCs/ECs for
clinical applications.
In contrast to previous methods, in step I of culture (days
0–6) we neither induced adherence in the EPC culture
from the beginning nor simply expanded the CD34+ cells
in suspension; we used a combination of high-level VEGF
(50 ng/ml) with other stem cell growth factors (SCF, TPO,
FLT-3, IL-3, and GM-CSF). Under the stimulation of this
novel cytokine combination, CD34+ cells, including the
early EPCs, maintained a robust proliferation rate without
Fig. 5 Transplantation of human EPCs/ECs into the livers of NOD/SCID mice. a Acute liver injury was induced in mice by an intraperitoneal
injection of 100 mg/kg MCT in the control, trans-7d, trans-14d, and trans-28d groups. EPCs/ECs infected with GFP lentivirus were transplanted into
mice in the blank, trans-7d, trans-14d, and trans-28d groups (6 × 106 cells in 100 μl PBS per mouse) via the hepatic portal vein while the control
group mice were treated with 100 μl PBS. At days 7, 14, and 28 after transplantation, mice in the trans-7d, trans-14d, and trans-28d groups were
sacrificed by cervical dislocation, respectively, hepatic tissues were obtained to make cryosections (20 μm), and the GFP-positive cells were
detected using immunofluorescent staining. In the control and blank groups, mice were sacrificed and hepatic tissues were analyzed 7 days
after transplantation. Scale bar = 50 μm. b Percentages of GFP-positive cells in the mouse livers were analyzed by ImageJ software. Twenty-five
cryosections per mouse (n = 8 each group) were calculated. Data are mean ± SD. **P < 0.01. DAPI 4,6-diamidino-2-phenylindole, GFP green
fluorescent protein
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significant changes in morphology. Within 6 days, the pro-
liferation fold of CD34+ cells and VEGFR-2+ cells was 108
± 15.6 and 41.9 ± 5.1, respectively, which determined the
final yield of expanded EPCs.
In step II of culture (days 7–21) total cells were trans-
ferred to the EBM-2 medium in FN-coated plates, and a
low concentration of VEGF (25 ng/ml) combined with
other endothelial growth factors (IGF, EGF, and b-FGF)
was added to enhance the generation of EPCs. This cul-
ture condition on the one hand promoted the proliferated
CD34+ cells to further differentiate towards endothelial
lineage, and on the other stimulated the existing and
newly generated EPCs to adhere to the plates and grow
exponentially. On day 21, a large number of functional
EPCs/ECs were obtained with a purity of 99% (Fig. 3).
As regards the efficiency evaluation of EPCs/ECs, we
developed a NOD/SCID mouse model with hepatic si-
nusoidal endothelium injury to verify the engraftment
capacity of generated human EPCs/ECs [7]. Because of
the high cross-reactivity of human and mouse functional
proteins, we were unable to detect human FVIII or vWF
in the mouse liver sections. However, we verified the
endothelial secretion of these proteins before transplant-
ation (Fig. 3b, c). Moreover, in order to enhance the
fluorescence signal in GFP-positive cells, we used an
anti-GFP primary antibody followed by a fluorescently
labeled secondary antibody to verify the presence of hu-
man EPCs/ECs. The results from day 7 post transplant-
ation showed that most of the GFP-positive cells could
be observed around the endothelium of small veins in
the hepatic issues. Subsequently, on day 14, they were
found to scatter in the intercellular spaces between he-
patocytes at the hepatic plates. These results indicated
that the human EPCs/ECs first adhered to the vascular
inner wall after injection via the hepatic portal vein, and
then gradually migrated to the sites of injury induced by
MCT in the hepatic sinusoidal endothelium. These ob-
servations revealed significant chemotaxis toward the in-
jured sites and migration activity of the injected human
EPCs/ECs. However, no GFP-positive cells were detected
on day 28. One possible explanation for this is that GFP
is strongly immunogenic [29, 30], so implanted EPCs/
ECs expressing GFP might be ablated gradually by the
host due to immunological rejection. In addition, the
current mouse model was established with NOD/SCID
mice, which can have activated macrophages that may
cause destruction of donor cells.
During a 6-month observation period, besides the
MCT-induced injury, no tumor formation or other in-
duced pathological problems were detected in our study.
On the basis of the in-vivo studies, we can claim that
the human EPCs/ECs produced using our two-step sys-
tem can successfully survive and safely exist in vivo for
more than 2 weeks. If this approach is applied to the
treatment of hemophilia A, the persistent FVIII secre-
tion will innovatively reduce patients’ dependency on ex-
pensive recombinant human FVIII. In addition, because
human leukocyte antigen (HLA) matching is extremely
strict for ECs, transplantation of autologous EPCs/ECs
as a personalized treatment may also provide satisfactory
therapeutic effects in clinical applications. We also
achieved successful expansion and differentiation of
EPCs derived from human mobilized peripheral blood
CD34+ cells by the two-step system, further improving
the clinical value of this technology.
Conclusion
We describe an approach for the generation of cord
blood-derived EPCs/ECs on a large scale, characterize
them phenotypically, and demonstrate their in-vivo
functional capacity. Our study strongly indicates that the
two-step culture system can be developed into an in-
novative technology for industrial production of human
EPCs/ECs derived from cord blood. In our future work,
we will further evaluate the safety and efficacy of this
technology in a nonhuman primate model. This preclin-
ical research will promote the cell therapy application of
high-efficiency ex-vivo expansion of EPCs in ischemic
disease and hemophilia A.
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